Abstract:Abstract Statement of Purpose: Glioblastoma (GBM) is the most common and lethal form of brain cancer. Despite an aggressive treatment strategy, including surgical resection followed by radio- and chemotherapy, GBM has one of the highest mortality rates among all human tumors. The leading causes of this devastating prognosis are rapid recurrence and therapeutic resistance; current chemo- and immunotherapies fail to control tumor growth and progression. Temozolomide (TMZ) remains the gold standard for GBM treatment since its FDA approval for GBM in 2005. Subsequently, GBM treatment strategy has seen no significant advancement, despite TMZ providing only minimal benefit to most patients. Recent efforts to develop novel therapies for GBM have primarily involved in vivo animal models and conventional 2D cell cultures. However, animal models do not allow for elucidating specific interactions between cancer cells and tumor microenvironment (TME), while 2D models fail to depict the complex tumor architecture. In vitro biomaterial models offer an opportunity to evaluate aspects of cell-cell and cell-matrix driven responses within the complex TME. Here, we construct and validate a 3D hydrogel platform to evaluate drug response in GBM and to examine the role of TME in drug response, resistance, and local invasion. Results: Our model departs from most biomaterial platforms by assessing a wide range of TMZ concentrations and further validating drug response at low doses. Moreover, we use a set of GBM cell lines with defined shifts in TMZ response. These lines are an ideal candidate to model TMZ response & resistance—a unique set of isogenically matched GBM cells (8MGBA vs. 8MGBA-TMZres; 42MGBA vs. 42MBGA-TMZres). This set exhibits TMZ responsiveness or resistance along with disparate proliferative and invasive patterns. Here, we analyze these cell models in GelMA hydrogels to elucidate mechanisms underlying the acquired TMZ resistance in GBM tumors. We validate our platform by using physiologically relevant TMZ doses, showing the possibility to study TMZ response in 3D at low, physiologically relevant (< 100 μM) concentrations. We determine the growth-rate (GR) inhibition, GR50, IC50, and metabolic activity to benchmark detection limits for acquired TMZ resistance in the engineered GelMA GBM model. Subsequently, we use WT and TMZres variants of 42MGBA and 8MGBA lines to determine the upper and lower bounds of detectable TMZ response in 3D GelMA hydrogels. These quantified shifts in TMZ-induced GR inhibition are a key benchmark for studies of the efficacy of novel therapeutics in patient-derived GBM models. Furthermore, we assess the effect of acquired drug resistance on local invasion of GBM. Ongoing experiments aim to adapt our platform for phenotypic drug screening and target validation of novel small-molecule therapeutics. Citation Format: Viktoriia Kriuchkovskaia, Brendan A. Harley, Rebecca B. Riggins. A three-dimensional model of glioblastoma for discovery of novel therapeutics. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4579.

Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels

Abstract 6770: Acquired temozolomide resistance instructs patterns of glioblastoma cell motility and proteome expression within gelatin hydrogels

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

Microphysiological system modeling pericyte-induced temozolomide resistance in glioblastoma

Temozolomide resistance in glioblastoma multiforme

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

Abstract P20: Unveiling the Influence of Tumor Microenvironment and Spatial Heterogeneity on Temozolomide Resistance in Glioblastoma using an Advanced Human in vitro Model of the Blood-brain Barrier and Glioblastoma

Abstract 4579: A three-dimensional model of glioblastoma for discovery of novel therapeutics

Abstract 2501: A glioblastoma and blood-brain barrier in vitro model to assess the tumor microenvironment and temozolomide resistance

Dddr-45. Investigating Temozolomide Resistance In Glioblastoma Using A Clinically Relevant Dosing Regimen

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Biom-64. Exploiting Cell-Free Dna To Dissect Mechanisms Of Resistance To Temozolomide In Glioblastoma Cells

Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance

Considering the Experimental Use of Temozolomide in Glioblastoma Research

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

Differential Characterization of Temozolomide-Resistant Human Glioma Cells

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review